PsyMetRiC is getting bigger and better
Bear with us while we implement some big changes. We'll be back soon!
To stay informed of our progress, register your email address below.
Welcome to the Psychosis Metabolic Risk Calculator App – an innovative tool for assessing cardiometabolic risk in young people with psychosis.
Principal Investigator
Benjamin I. Perry Associate Clinical Professor of Psychiatry
Institute for Mental Health
PsyMetRiC Research Group
Emanuele F. Osimo Clinical Lecturer in Psychiatry
Department of Psychiatry
Shuqing Si Research Fellow
Institute for Mental Health
Clara Lewis Data Scientist
Institute for Mental Health
Ben Laws Research Fellow
Department of Psychiatry
Karla Hitchins Research Associate / PhD Student
Institute for Mental Health
Jasmine Hundal Clinical Fellow
Institute for Mental Health
James Hotham Clinical Fellow
Institute for Mental Health
Expert Advisory Group
Joie Ensor Associate Professor of Biostatistics
Applied Health Sciences
Graham M. Murray Professor of Psychiatry
Department of Psychiatry
Rachel Upthegrove Professor of Psychiatry
Institute for Mental Health
Simon J. Griffin Professor of General Practice
Department of Public Health & Primary Care
Golam M. Khandaker Professor of Psychiatry
Bristol Medical School
David Shiers OBE Honorary Reader, Retired GP and Carer
Psychosis Research Unit
Richard I.G. Holt Professor of Diabetes and Endocrinology
Faculty of Medicine
Peter B. Jones Professor of Psychiatry
Department of Psychiatry
Carolyn Chew-Graham OBE Professor of General Practice Research
School of Medicine
Xiaoxuan Liu Associate Professor in AI and Digital Health
Applied Health Sciences
Alastair K. Denniston Professor of Regulatory Science & Innovation
Applied Health Sciences
Lived Experience Advisory Panel
Ashley
Carina
Zaynab
Antonio
Billie
Hannah
Chelsea
Sunniva
Collaborators
Jackie Curtis Conjoint Professor of Psychiatry
UNSW
Phil Ward Professor of Psychiatry
UNSW
Scott Teasdale Senior Research Fellow
UNSW
Javier Vazquez-Bourgon Assistant Professor of Psychiatry
Universidad de Cantabria
Nathalia Garrido-Torres Psychiatrist
Hospital Universitario Virgen del Rocio
Benedicto Crespo-Facorro Professor of Psychiatry
Hospital Universitario Virgen del Rocio
Frederik Vandenberghe Clinical Pharmacist
Lausanne University Hospital
Chin B. Eap Professor of Psychiatry
Lausanne University Hospital
Jaakko Keinänen Clinical Lecturer
University of Helsinki
Saana Eskelinen General Practitioner & Researcher
University of Helsinki
Jaana Suvisaari Professor of Psychiatry
Finnish Institute for Health and Welfare
Jarmo Hietela Professor of Psychiatry
University of Turku
Sébastien Brodeur Psychiatrist & Researcher
Université Laval
Marie France Demers Professor of Pharmacy
Université Laval
Sri Mahavir Agarwal Associate Professor of Psychiatry
University of Toronto
Margaret Hahn Professor of Psychiatry
University of Toronto
Sherry Chan Clinical Associate Professor
Hong Kong University
Wing Tse Research Associate
Hong Kong University
Gerardo Zavala Gomez Research Fellow
University of York
Najma Siddiqi Professor of Psychiatry
University of York
With Support From
PsyMetRiC
Version: 1.0
Manufacturer:
University of Birmingham Enterprise Limited
University of Birmingham, Edgbaston, Birmingham, B15 2TT
Date of Last Update:
01/07/2025
Instructions:
Consult this page and the embedded help pages for correct use.
Warning:
PsyMetRiC is designed to inform clinical decisions but should not dictate them. Clinical decisions should rely on a range of information including patient preference.
Performance of PsyMetRiC is reliant upon an internet connection.
Intended Use:
PsyMetRiC is a prediction algorithm software which predicts the future development of cardiometabolic disorders in those who have experienced their first presentation of a psychotic disorder between the ages of 16–35. It is intended for use by health professionals within NHS clinical services.
Classification: Class I Medical Device under UK MDR 2002
Serious Incident Reporting:
If a user experiences a serious incident, this should be reported to the manufacturer at [email protected] and to the MHRA.
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Significant Weight Gain
Details about Significant Weight Gain will be here...
Metabolic Syndrome
Among 100 people with the same risk factors as you,
will develop this outcome.
Coming Soon...
Type 2 Diabetes
Details about Type 2 Diabetes will be here...
Risk Communication Resources
Download a co-produced guide to assist with risk communication.
Download Risk Communication GuideContact information will be stored and used in accordance with our Privacy Policy. The MailerLite service will be used to send email updates. See the MailerLite Security Statement for further information.
Privacy PolicyMailerLite Security Statement
We are always looking for researchers from anywhere in the world to join our international collaborative effort toward a future globally-useful risk prediction tool for the primary prevention of cardiometabolic morbidity and mortality in psychosis. If you are interested in joining forces with us, or have data that could be used to help validate or improve PsyMetRiC we'd be delighted to hear from you!
Siempre estamos buscando investigadores de cualquier parte del mundo para unirse a nuestro esfuerzo colaborativo internacional. Hacia una futura herramienta de predicción de riesgos globalmente útil para la prevención primaria de la morbilidad y mortalidad cardiometabólica en la psicosis. Si usted está interesado en unir fuerzas con nosotros o tiene datos que podrían usarse para ayudar a validar o mejorar PsyMetRiC ¡Estaremos encantados de saber de usted!
Nous sommes toujours à la recherche de chercheurs de partout dans le monde pour se joindre à notre effort de collaboration internationale. vers un futur outil de prévision des risques utile à l’échelle mondiale pour la prévention primaire de la morbidité et de la mortalité cardiométaboliques liées à la psychose. Si tu êtes intéressés à unir nos forces avec nous, ou disposez de données qui pourraient être utilisées pour aider à valider ou améliorer PsyMetRiC nous serions ravis d'avoir de vos nouvelles!
Etsimme tutkijoita kansainväliseen yhteistyöhön tarkoituksenamme kehittää riskilaskuri psykoosia sairastavien kardiometabolisen sairastuvuuden ja siihen liittyvän kuolleisuuden ehkäisyyn. Jos olet kiinnostunut yhteistyöstä PsyMetRiC:n validoimisessa tai kehittämisessä olisimme iloisia yhteydenotostasi!
PsyMetRiC Privacy Notice
This privacy notice explains how we handle your personal information when you use the PsyMetRiC web app.
Contact Details
To contact the PsyMetRiC team, please use the feedback form available on the app.
What information we collect and why
- Calculator Inputs: Information entered to generate a risk score is processed locally in your browser and not stored or shared.
- Feedback: You may submit feedback through an encrypted web form, optionally including your name or email address.
- Mailing List: If you opt in, we collect your email to send updates.
- Server Logs: We collect anonymous technical data (IP address, page visits). Logs are reset every 24 hours and do not include clinical inputs.
- Analytics: We use Google Analytics to monitor general usage trends. This includes anonymised IPs, device type, and behaviour data. No clinical input data is collected or shared.
Lawful Bases
- Risk calculator inputs: Explicit consent (by using the tool)
- Feedback and email updates: Legitimate interest
- Analytics: Consent (via cookie banner)
- Special category data: Explicit consent under UK GDPR Article 9(2)(a)
How long we keep information
Feedback and mailing list data will be securely retained for up to 10 years for regulatory compliance.
Who we share information with
We use the following GDPR-compliant data processors:
Mailerlite
Provides mailing list functionality. Data is securely stored in the EU (ISO 27001 certified).
Jotform
Hosts our feedback form. Data is encrypted and stored in the EU (ISO 27001 certified).
Google Analytics
Used to understand app usage trends. IP anonymisation is enabled. No health data is collected or shared.
Analytics and Cookies
We use Google Analytics to help us understand general usage patterns and improve the app. This includes anonymised data such as device type, browser, and number of visits.
No risk calculation data or user-submitted health information is collected by Google Analytics.
Our app includes a cookie banner (via Civic Cookie Control) to request your consent before enabling analytics cookies. You can change your cookie preferences at any time using the banner settings.
International Transfers
Where needed, personal data may be transferred outside the UK in line with the UK GDPR and appropriate safeguards.
Your Data Protection Rights
Under data protection law, you have the right to:
- Access your personal data
- Request correction or deletion
- Object to or restrict processing
- Withdraw consent
- Request data portability
You do not need to pay a fee to exercise these rights. If you make a request, we have one calendar month to respond.
How to Complain
If you have concerns about our handling of your data, please contact us first. If you are not satisfied, you can complain to the Information Commissioner's Office (ICO):
Information Commissioner's Office
Wycliffe House, Water Lane
Wilmslow, Cheshire, SK9 5AF
Helpline: 0303 123 1113
Website: www.ico.org.uk/make-a-complaint